In-Depth Analysis of Novo Nordisk (NVO)'s M&A Capacity and Strategic Contraction Strategy

I have now collected sufficient data and information, and will provide you with a systematic and comprehensive analysis report.

---

January 13, 2026, Maziar Mike Doustdar, Novo Nordisk’s new CEO, made his first public appearance at the 44th J.P. Morgan Healthcare Conference, announcing the company’s major strategic restructuring [1]. This new leader’s first public speech conveyed several key signals:

: All future business expansions of the company must revolve around the core needs of diabetes or obesity patients, clearly defining strategic boundaries. This marks Novo Nordisk’s shift from a diversification strategy back to its core business areas [2].

: The company clearly stated that it has up to $40 billion in M&A capacity, while emphasizing that potential targets must be “value for money” [1]. This statement reflects the management’s responsible attitude towards shareholders’ capital and demonstrates the determination to maintain investment discipline in the current high-valuation environment.

: Doustdar clearly stated that the company will contract business areas unrelated to diabetes and obesity. All non-rare disease projects must start with diabetes or obesity patients, and other indications will only be considered if they are comorbidities of these diseases [2].

Doustdar openly acknowledged at the conference that 2025 was a difficult year for Novo Nordisk. Sales of GLP-1 drugs failed to meet market expectations, and the company faced multiple pressures [3]:

• Patent Expiration Risk
  : Semaglutide faces patent expiration in multiple markets
• Intensified Competition
  : Eli Lilly’s (Zepbound/Mounjaro) market share continues to rise
• Valuation Pressure
  : The stock price has fallen sharply from its peak, and investor confidence has been hit

---

Based on the latest financial data, Novo Nordisk has the financial strength to implement large-scale M&A [0]:

Financial Indicator	Value	Industry Position
Market Capitalization	$277.06 billion	One of the world’s largest diabetes/obesity drug developers
Free Cash Flow	$69.659 billion	TTM
ROE	66.95%	Excellent return on capital
Net Profit Margin	32.88%	Extremely strong profitability
Cash on Hand	Sufficient	Supports large-scale M&A

The company’s strong cash flow generation capacity and robust balance sheet provide solid support for its M&A strategy.

The “value for money” principle emphasized by Doustdar reflects the management’s clear understanding of the current biopharmaceutical M&A market:

:

• Obesity Pipeline Assets
  : Late-stage obesity R&D projects, especially candidate drugs with differentiated advantages
• Innovative Diabetes Therapies
  : Next-generation insulin, GLP-1 combination therapies, oral formulations
• Complementary Technologies for Metabolic Diseases
  : Such as AI-driven drug discovery platforms and drug delivery technologies

:

• Refuse to pay excessive premiums for “narratives”
• Focus on assets with clear clinical value and commercialization paths
• Emphasize synergies and integration feasibility

At the 2026 J.P. Morgan Healthcare Conference, M&A became a core topic [1]:

• Merck
  : Plans to invest approximately $40 billion in ADCs, bispecific antibodies, and other areas, and is in talks to acquire Revolution Medicines for up to $32 billion
• Eli Lilly
  : Acquired Venyx, a company focused on inflammation, for $1.2 billion
• Amgen
  : Fired the first shot in biotech M&A for 2026

Against this backdrop, Novo Nordisk’s $40 billion M&A capacity puts it in a favorable position in the competition for potential targets.

---

Novo Nordisk’s strategic contraction represents a partial reversal of its 2019 diversification strategy [2]. At that time, Chairman Helge Lund stated that “long-term success can only be achieved through product portfolio diversification”.

:

• Exit therapeutic areas not directly related to diabetes and obesity
• Suspend or terminate R&D projects for non-core indications
• Focus on the needs of the 2 billion diabetes and obesity patient population

:

• Full range of diabetes treatment options
• Obesity (with Wegovy/Ozempic as the core)
• Rare disease business (hemophilia, growth hormone, etc.)
• Liver diseases (metabolism-related indications such as NASH)

1. Optimized Resource Allocation
   : Concentrate R&D and commercial resources on core advantage areas
2. Improved Operational Efficiency
   : Streamline organizational structure and accelerate decision-making speed
3. Enhanced Professional Depth
   : Establish higher competitive barriers in the metabolic disease field
4. Improved Capital Efficiency
   : Exit inefficient businesses and improve overall investment returns

1. Limited Growth Space
   : Abandoning diversification may miss opportunities in other therapeutic areas
2. Concentrated Competition Risk
   : All resources are bet on direct competition with Eli Lilly
3. Patent Cliff Pressure
   : Core products face concentrated impact from patent expirations
4. Difficulty in Valuation Repair
   : A single business model may limit valuation imagination

---

The current global GLP-1 market presents a duopoly competitive pattern between Novo Nordisk and Eli Lilly [5][6]:

:

Company	2024 Market Share	2025 Trend	Competitive Advantage
Novo Nordisk	Approximately 60-70%	Declining	First-mover brand advantage, complete product portfolio
Eli Lilly	Approximately 30-40%	Rising rapidly	More potent efficacy, pricing flexibility

:

• Oral Formulation Competition
  : Novo Nordisk has been the first to obtain approval for oral Wegovy, and Eli Lilly’s orforglipron is expected to be approved in 2026 [4][6]
• Efficacy Differentiation
  : CagriSema (a combination of semaglutide + amylin) shows approximately 23% weight loss effect [3]
• Capacity Expansion
  : Both companies are investing heavily in production facilities

2026 has been positioned as the “Year of Oral Drugs” [4]. Novo Nordisk has gained a first-mover advantage in this field:

:

• Approved by the FDA in December 2025, becoming the first oral GLP-1 obesity drug
• No cold chain storage required, significantly reducing logistics costs
• Improves patient compliance and convenience
• Launched ahead of Eli Lilly’s orforglipron

:

• Oral formulations may account for approximately 24% (about $22 billion) of the global weight-loss drug market by 2030 [6]
• Oral formulations are expected to attract new patient groups and expand the total market capacity

Novo Nordisk submitted a New Drug Application (NDA) for CagriSema to the FDA in December 2025 [7]. This drug has the following characteristics:

:

• The first combined injection therapy of GLP-1 and amylin analog
• Administered once a week
• Approximately 23% weight loss effect (better than monotherapy)

:

• The FDA is expected to make an approval decision in 2026
• Expected to establish a differentiated position beyond Zepbound and Wegovy
• Provides a new option for patients who are resistant to or unresponsive to existing treatments

---

Novo Nordisk’s stock price has experienced significant fluctuations [0]:

Period	Return Rate	Notes
1-Day	+9.12%	Sharp rebound
5-Day	+3.64%	Uptrend continues
1-Month	+30.48%	Strong recovery
6-Month	-4.53%	Pullback under pressure
YTD	+18.97%	Significant recovery
1-Year	-20.79%	Pullback from highs
3-Year	-10.30%	Overall weakness
5-Year	+70.72%	Long-term positive

:

• Current Price: $62.33
• 52-Week Range: $43.08 - $93.80
• Support Level: $58.20
• Resistance Level: $62.40
• Next Target: $64.44

There are significant differences in valuation indicators between Novo Nordisk and Eli Lilly [0]:

Valuation Indicator	Novo Nordisk (NVO)	Eli Lilly (LLY)	Interpretation of Differences
Market Capitalization	$277.06 billion	$930.88 billion	LLY is larger
P/E	16.66x	50.58x	NVO is more valuation-attractive
P/B	10.18x	39.14x	NVO’s valuation is more reasonable
P/S	5.48x	11.50x	NVO is cheaper
EV/OCF	14.52x	59.99x	NVO has better cash flow returns

:
Novo Nordisk’s current P/E ratio (16.66x) is in a historically low range, with a discount of approximately 67% relative to Eli Lilly (50.58x). This discount partially reflects:

• 2025 performance fell short of expectations
• Market share being eroded by Eli Lilly
• Concerns about patent expiration
• Expectations of slowing growth

[3]:

Profitability Indicator	Novo Nordisk	Eli Lilly	Analysis
ROE	66.95%	1.02%	NVO has excellent capital efficiency
Net Profit Margin	32.88%	30.99%	Comparable
Operating Profit Margin	42.03%	43.86%	Slightly lower but strong
Current Ratio	0.78	1.55	NVO has weaker liquidity

Novo Nordisk’s ROE is as high as 66.95%, demonstrating extremely strong shareholder return capacity, far exceeding Eli Lilly’s 1.02%.

---

Based on technical analysis results [0]:

Indicator	Value	Signal Interpretation
MACD	Bullish crossover (no bearish crossover)	Upward momentum continues
KDJ	K:82.2, D:80.8	Overbought zone, be alert to pullback
RSI	Overbought risk	Short-term adjustment possible
Beta	0.36 (vs. SPY)	Low volatility characteristic

:

• Trend Type: Uptrend (to be confirmed)
• Status: Breakout day (to be confirmed)
• Trend Score: 4.0/5.0

:

• Resistance Levels
  : $62.40 (short-term), $64.44 (next target)
• Support Levels
  : $58.20 (short-term), 50-day moving average at approximately $50.62

:

• If it breaks through $62.40 and stabilizes, consider following up
• If it falls below $58.20, be alert to a deeper pullback
• Currently in an overbought zone, it is recommended to wait for a pullback before positioning

---

:

1. First-Mover Advantage and Brand Recognition
   • Has over 100 years of diabetes treatment history
   • Brand trust established by Ozempic/Wegovy
   • Prescribing habits of doctors and patients

2. Complete Product Portfolio
   • Injectable formulations (Wegovy, Ozempic)
   • Oral formulations (Rybelsus, oral Wegovy)
   • Combination therapies (CagriSema)
   • Insulin product line

3. R&D Depth
   • Late-stage pipeline: CagriSema, 7.2mg high-dose semaglutide
   • Early-stage pipeline: Multiple obesity and diabetes projects in R&D
   • Amylin biology as a core research area

4. Manufacturing Capabilities
   • Approximately 78,500 employees
   • Operations in approximately 80 countries
   • Strong global commercialization capabilities

1. Market Share Loss
   • Eli Lilly’s Mounjaro/Zepbound is rapidly seizing market share
   • 2025 GLP-1 sales fell short of expectations

2. Patent Expiration Pressure
   • Core patents for semaglutide are about to expire
   • Facing competition from generics and biosimilars

3. Valuation Discount
   • Market concerns about slowing growth
   • Analyst target price is a 24.6% discount to the current price

Based on comprehensive assessment:

Strategic Factor	Novo Nordisk Score (1-10)	Eli Lilly Score (1-10)
M&A Capacity	10	10
R&D Focus	9	10
Cost Control	8	7
Liquidity	9	6
Growth Prospects	7	8
Total Score	43	41

Novo Nordisk has advantages in cost control and liquidity, while Eli Lilly has a slight edge in R&D focus and growth prospects.

---

1. Valuation Attractiveness
   • P/E is only 16.66x, a historically low level
   • Approximately 67% discount compared to Eli Lilly
   • High ROE (66.95%) demonstrates excellent capital efficiency

2. Product Portfolio Upgrade
   • Oral Wegovy approved, providing new growth drivers
   • CagriSema NDA submitted to FDA, releasing pipeline value
   • 7.2mg high-dose semaglutide is about to be commercialized

3. Market Expansion Potential
   • 2 billion diabetes and obesity patients worldwide
   • Oral formulations expand patient access
   • Growth opportunities in emerging markets

4. M&A Capacity
   • $40 billion M&A firepower
   • Can quickly strengthen the pipeline or acquire key technologies
   • Maintain flexibility in a highly competitive market

1. Intensified Competition Risk
   • Sustained challenges from Eli Lilly
   • Threats from new entrants (Viking, Pfizer, etc.)
   • Price competition may compress profit margins

2. Patent Expiration Risk
   • Significant revenue decline after semaglutide patent expiration
   • Continuous innovation is required to maintain market position

3. Execution Risk
   • The new CEO’s strategic adjustments need time to be verified
   • Uncertainty in M&A target selection and integration
   • Challenges in the promotion of oral Wegovy

4. Macroeconomic Risks
   • Healthcare payment pressure
   • Political scrutiny (disputes over price increases)

Based on the latest data [0]:

:

• Strong Buy: 2.6%
• Buy: 61.5%
• Hold: 28.2%
• Sell: 7.7%

:

• Consensus Target: $47.00 (24.6% discount to current price)
• Target Range: $42.00 - $54.00
• Analyst Consensus Score: 47.5 (Buy)

:

• December 8, 2025: Argus Research downgraded to Hold
• November 28, 2025: Goldman Sachs maintained Buy
• November 24, 2025: HSBC downgraded to Hold

Investment Type	Recommendation	Rationale
Long-Term Investment	Consider Holding	Valuation is attractive, core business is solid
Short-Term Trading	Cautious	High volatility, wait for better entry points
Value Investment	Worth Paying Attention To	P/E is at a historically low level, fundamentals are robust
Growth Investment	Less Attractive	Slowing growth, valuation discount

---

The M&A capacity and strategic contraction strategy announced by Novo Nordisk’s new CEO Doustdar at the 44th J.P. Morgan Healthcare Conference have the following impacts on the company’s market competitiveness and long-term investment value:

:

1. Resource Focus
   : Concentrate R&D and commercial resources on the core areas of diabetes and obesity, which is expected to improve operational efficiency
2. Strengthened Competitive Barriers
   : Establish a deeper moat in the metabolic disease field
3. Clear Investor Communication
   : A clear strategic direction helps the market understand the company’s value

:

1. Maintain Flexibility
   : Maintain strategic initiative in a rapidly changing market
2. Pipeline Supplement
   : Can quickly acquire late-stage assets or complementary technologies
3. Competitive Advantage
   : Occupy a favorable position in the wave of industry M&A and integration

:

1. Strategic contraction may limit growth space
2. Uncertainty in M&A execution
3. Competition with Eli Lilly will continue to intensify

:

• FDA approval decision for CagriSema
• Commercialization progress of oral Wegovy
• Launch of 7.2mg high-dose semaglutide
• Quarterly performance exceeding expectations

:

• Eli Lilly’s orforglipron may be approved
• Impact of patent expiration becomes apparent
• Market competition continues to intensify

:

• Successful M&A to obtain blockbuster assets
• CagriSema becomes a new growth engine
• Oral formulations expand market leadership
• Valuation recovers to historical average

:

• Continued market share loss